Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

800902

registered interest
date	05/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Misuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to tackle opioid abuse in the homeless community.
tabling member constituency	East Kilbride, Strathaven and Lesmahagow
tabling member printed	Dr Lisa Cameron
uin	117461
answer	answer is ministerial correction date of answer 13/12/2017 answer text <p>The Government is investing £16 billion over the Spending Review period for local authorities (LAs) to spend on public health. LAs are responsible for making decisions on how to spend their local allocation but the public health grant conditions make it clear that they must have regard for the need to improve the take up of, and outcomes from, their drug and alcohol misuse treatment services. Public Health England guidance, developed with drug service providers, promotes the need for local authorities, commissioners and healthcare providers to work together to create systems and pathways that enable people who use drugs, including those who experience homelessness, to access services.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/12/2017 14:07:33 answering member 4067 label Biography information for Steve Brine
tabling member	4412 label Biography information for Dr Lisa Cameron

800913

registered interest
date	05/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions his Department has had with NHS England on whether breast cancer patients who currently receive Herceptin (trastuzumab) in the subcutaneous formulation will be included in their ambition for 80 per cent of existing patients being on the best value biological medicine within 12 months.
tabling member constituency	West Ham
tabling member printed	Lyn Brown
uin	117472
answer	answer is ministerial correction date of answer 13/12/2017 answer text <p>Through its Medicines Value Programme, NHS England aims to deliver best value for medicines used in the National Health Service. Use of best value biologics is part of this programme which will drive rapid uptake of biosimilar medicines in the NHS. Trastuzumab is currently available as two products – one for intravenous (IV) use and the other for subcutaneous use. We are expecting several biosimilars of the IV preparation to be available sometime in 2018. As part of the medicines value programme we expect 80% uptake of the best value biologic within 12 months – this applies only to the IV preparation.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/12/2017 15:25:02 answering member 4067 label Biography information for Steve Brine
tabling member	1583 label Biography information for Ms Lyn Brown

800927

registered interest
date	05/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drug: Misuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the Advisory Council on the Misuse of Drugs report Commissioning impact on drug treatment which published in September 2017, what assessment he has made of the effect of reductions in funding for local authorities on the availability of drug misuse treatment in England.
tabling member constituency	Manchester, Withington
tabling member printed	Jeff Smith
uin	117486
answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>Officials are currently reviewing the report by the Advisory Council on the Misuse of Drugs entitled Commissioning impact of on drug treatment published on 6 September. The Government will respond shortly.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/12/2017 17:39:29 answering member 4067 label Biography information for Steve Brine
tabling member	4456 label Biography information for Jeff Smith

800952

registered interest
date	05/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of trends in the rates of prostate cancer among men over 50 who are (a) white and (b) BAME during the last ten years.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	117511
answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>Data on the rates of prostate cancer among men over 50 are not held in the format requested.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/12/2017 17:37:22 answering member 4067 label Biography information for Steve Brine
tabling member	1409 label Biography information for Mr Gregory Campbell

800962

registered interest
date	05/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Infant Foods: Marketing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health what assessment he has made of the potential merits of fully implementing the International Code of Marketing of Breastmilk Substitutes after the UK leaves the EU.
tabling member constituency	Glasgow Central
tabling member printed	Alison Thewliss
uin	117521
answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>The Infant Formula and Follow-on Formula Regulations 2007 implements European Commission Directive 2006/141/EC on infant formulae and follow-on formulae, which gives effect to the principles and aims of the 1981 World Health Organization Code on the Marketing of Breastmilk Substitutes dealing with marketing, information and responsibilities of health authorities. There are no plans to review this legislation after the United Kingdom leaves the European Union.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/12/2017 17:40:18 answering member 4067 label Biography information for Steve Brine
tabling member	4430 label Biography information for Alison Thewliss

800970

registered interest
date	05/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Patients: Transport
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, which Minister of his Department has responsibility for non-emergency patient transport.
tabling member constituency	Carshalton and Wallington
tabling member printed	Tom Brake
uin	117529
answer	answer is ministerial correction date of answer 13/12/2017 answer text <p>I have portfolio responsibility for the commissioning of non-urgent patient transport.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/12/2017 14:00:40 answering member 4067 label Biography information for Steve Brine
tabling member	151 label Biography information for Tom Brake

800983

registered interest
date	05/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether there are plans to extend the cancer dashboard to include tumour-specific data for (a) ovarian and (b) other less common cancers.
tabling member constituency	North East Derbyshire
tabling member printed	Lee Rowley
uin	117542
answer	answer is ministerial correction date of answer 13/12/2017 answer text <p>The initial focus of the cancer dashboard was to report on tumours with the highest incidence rates. NHS England intends to explore other tumour types in the dashboard over time. However, it is important to note that it will not be possible to include detailed data on some rarer cancers at clinical commissioning group level due to the low number of cases. It may be possible to include data on these cancers by larger geographical areas, such as Cancer Alliances or Sustainability and Transformation Partnership areas.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/12/2017 14:02:10 answering member 4067 label Biography information for Steve Brine
tabling member	4652 label Biography information for Lee Rowley

800996

registered interest
date	05/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Shingles: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to increase the rates of uptake of the shingles vaccine
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	117555
answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>In conjunction with NHS England and the Department, the eligibility criteria for this vaccine have been changed to make it easier for health care professionals (HCPS) to identify eligible patients. This change means that patients become eligible for the vaccine from their 70th and 78th birthdays (if not previously vaccinated) and can be offered the vaccine opportunistically all year round.</p><p> </p><p>In support of this change, Public Health England has updated communication materials to both patients and HCPs to better illustrate eligible cohorts. This includes guidance for those in age groups with previous eligibility who have missed the opportunity to receive the vaccine, up to their 80th birthday.</p><p> </p><p>NHS England has a focus on reducing variation in all Section 7a immunisation programmes and work with local teams to seek assurance that low uptake and variation are addressed, and to identify good practice that can be shared.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/12/2017 17:43:52 answering member 4067 label Biography information for Steve Brine
tabling member	4243 label Biography information for Dan Jarvis

801009

registered interest
date	05/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Misuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 22 November 2017 to Question 113472, for what reasons the period from April 2010 to March 2013 was excluded from the total amount of money from the public purse spent on Talk to Frank since its creation.
tabling member constituency	South Thanet
tabling member printed	Craig Mackinlay
uin	117568
answer	answer is ministerial correction date of answer 13/12/2017 answer text <p>The Talk to FRANK service is currently operated by Public Health England (PHE), and the information supplied in response to Question 113472 was drawn from PHE financial records.</p><p> </p><p>During the period April 2010 to March 2013, the Talk to FRANK service was operated jointly by the Home Office and the Department of Health.</p><p> </p><p>In the 2017 report ‘An evaluation of the Government’s Drug Strategy 2010’, the Government spend on media and information activity under the Drug Strategy 2010, 2010/11 to 2014/15 (including on FRANK) is provided on page 73:</p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/628100/Drug_Strategy_Evaluation.PDF" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/628100/Drug_Strategy_Evaluation.PDF</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/12/2017 14:05:23 answering member 4067 label Biography information for Steve Brine
tabling member	4529 label Biography information for Craig Mackinlay

801021

registered interest
date	05/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Novartis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the potential effect of the relocation of the European Medicines Agency on the future of the Novartis pharmaceutical (a) site and (b) production at that site.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	117580
answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>The Government is committed to ensuring a positive outcome for the whole life science sector that enhances competitiveness and builds on the success that we are rightly proud of, as we exit the European Union. Officials across government have been carrying out a programme of sectoral and regulatory analysis to identify the key factors for the life sciences sector that will affect our negotiations with the EU. Ultimately it is for the European Medicines Agency to comment on how it intends to operate from its new location, and what individual companies like Novartis might have to do differently.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/12/2017 17:40:39 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn